抗体发现：利用转基因小鼠生成用于治疗的人源单克隆抗体。

Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.

作者信息

Kellermann Sirid Aimée, Green Larry L

机构信息

Abgenix, Inc., 6701 Kaiser Drive, Fremont, CA 94555, USA.

出版信息

Curr Opin Biotechnol. 2002 Dec;13(6):593-7. doi: 10.1016/s0958-1669(02)00354-3.

DOI:10.1016/s0958-1669(02)00354-3

PMID:12482519

Abstract

Technical advances made in the 1980s and early 1990s resulted in monoclonal antibodies that are now approved for human therapy. Novel transgenic mouse strains provide a powerful technology platform for creating fully human monoclonal antibodies as therapeutics; ten such antibodies have entered clinical trials since 1998 and more are in preclinical testing. Improved transgenic mouse strains provide a powerful technology platform for creating human therapeutics in the future.

摘要

20世纪80年代和90年代初取得的技术进步催生了如今已获批用于人类治疗的单克隆抗体。新型转基因小鼠品系为制造全人源单克隆抗体作为治疗药物提供了一个强大的技术平台；自1998年以来，已有10种此类抗体进入临床试验，还有更多抗体正处于临床前测试阶段。改良后的转基因小鼠品系为未来制造人类治疗药物提供了一个强大的技术平台。